Entry |
|
Name |
Dapiprazole (INN) |
Formula |
C19H27N5
|
Exact mass |
325.2266
|
Mol weight |
325.45
|
Structure |

|
Simcomp |
|
Class |
Ophthalmic agent
DG03201 Intraocular pressure lowering agent
|
Remark |
Product (DG01140): | D03648<US> |
|
Efficacy |
Antiglaucoma, Neuroleptic, alpha-Adrenergic receptor antagonist |
Target |
|
Pathway |
hsa04080 | Neuroactive ligand-receptor interaction |
hsa04270 | Vascular smooth muscle contraction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01EX Other antiglaucoma preparations
S01EX02 Dapiprazole
D07775 Dapiprazole (INN)
Drug groups [BR:br08330]
Ophthalmic agent
DG03201 Intraocular pressure lowering agent
DG01140 Dapiprazole
D07775 Dapiprazole
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1
D07775 Dapiprazole (INN)
Drug groups [BR:br08330]
Ophthalmic agent
DG03201 Intraocular pressure lowering agent
DG01140 Dapiprazole
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 24
1 C1x C 13.7900 -24.4300
2 C1x C 13.7900 -25.8300
3 C1x C 15.0024 -26.5300
4 C8y C 16.2149 -25.8300
5 N4y N 16.2149 -24.4300
6 C1x C 15.0024 -23.7300
7 N5x N 17.5464 -26.2626
8 N5x N 18.3693 -25.1300
9 C8y C 17.5464 -23.9974
10 C1b C 17.9775 -22.6706
11 C1b C 19.3569 -22.3774
12 N1y N 20.3195 -23.4469
13 C1x C 19.8840 -24.7868
14 C1x C 20.8207 -25.8273
15 N1y N 22.1901 -25.5364
16 C1x C 22.6256 -24.1965
17 C1x C 21.6889 -23.1560
18 C8y C 23.1335 -26.5843
19 C8x C 22.4035 -27.8144
20 C8x C 23.0834 -29.0382
21 C8x C 24.4832 -29.0613
22 C8x C 25.2159 -27.8391
23 C8y C 24.5360 -26.6153
24 C1a C 25.2746 -25.3902
BOND 27
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 4 7 2
8 7 8 1
9 8 9 2
10 5 9 1
11 9 10 1
12 10 11 1
13 11 12 1
14 12 13 1
15 13 14 1
16 14 15 1
17 15 16 1
18 16 17 1
19 12 17 1
20 15 18 1
21 18 19 2
22 19 20 1
23 20 21 2
24 21 22 1
25 22 23 2
26 18 23 1
27 23 24 1
|